NO930453L - Vaksine og behandlingsmetode for human immunsviktvirus - Google Patents
Vaksine og behandlingsmetode for human immunsviktvirusInfo
- Publication number
- NO930453L NO930453L NO93930453A NO930453A NO930453L NO 930453 L NO930453 L NO 930453L NO 93930453 A NO93930453 A NO 93930453A NO 930453 A NO930453 A NO 930453A NO 930453 L NO930453 L NO 930453L
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- vaccine
- virus
- envelope
- aids
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000036039 immunity Effects 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 5
- 208000030507 AIDS Diseases 0.000 abstract 3
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229940124718 AIDS vaccine Drugs 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 241000238631 Hexapoda Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Ervervet immunsvlktsyndrom (AIDS) vaksine inneholdende humanimmunsviktvirus, type-1 (HIV-1) envelope proteiner blir produsert fra klonede HIV-1 envelope gener i et baculovlrus-insektcellevektorsystem. Bekomblnante EIV- 1-protelner blir renset, sammenstilt til partikler og deretter adsorbert på en aluminlumfosfatad;) uvant. Den resulterende adsorberte rekombinante HIV-1-vlrus envelope protein formuleringen (AIDS-vaksine) er sterkt Iminunogenlsk l dyr og danner antistoffer som blir bundet til HIV-1-virus envelope og nøytraliserer infektlviteten av viruset i in vltro tester. Overnevnte AIDS-vakslne Induserer nye humorale og cellulære Immunresponser i HIV-infiserte pasisenter og er nyttige som en form for vaksineterapi for å forsinke eller forhindre ødeleggelse av immunsystemet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71415291A | 1991-06-11 | 1991-06-11 | |
| PCT/US1992/004980 WO1992022654A1 (en) | 1991-06-11 | 1992-06-10 | Vaccine and treatment method of human immunodeficiency virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO930453D0 NO930453D0 (no) | 1993-02-09 |
| NO930453L true NO930453L (no) | 1993-02-09 |
Family
ID=26784830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO93930453A NO930453L (no) | 1991-06-11 | 1993-02-09 | Vaksine og behandlingsmetode for human immunsviktvirus |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BR9205290A (no) |
| NO (1) | NO930453L (no) |
-
1992
- 1992-06-10 BR BR9205290A patent/BR9205290A/pt not_active Application Discontinuation
-
1993
- 1993-02-09 NO NO93930453A patent/NO930453L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO930453D0 (no) | 1993-02-09 |
| BR9205290A (pt) | 1994-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6136321A (en) | Method of inactivating lipid-enveloped viruses | |
| ES2435095T3 (es) | Vacuna del Nilo Occidental | |
| Barrett et al. | Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity | |
| Thapar et al. | Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM) | |
| NO863803L (no) | Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). | |
| Prinzie et al. | Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain | |
| DK0610250T3 (da) | Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf | |
| AU1875099A (en) | Vaccines with an ltb adjuvant | |
| ES8706209A1 (es) | Un procedimiento para la preparacion de un proteina envolvente de un virus de sindrome de inmunodeficiencia adquirida | |
| WO1989002277A3 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
| DK273384A (da) | Levende adjuvansholdige vacciner og fremgangsmaader til fremstilling af saadanne vacciner | |
| US5766601A (en) | Cross-reactive influenza a immunization | |
| AR004464A1 (es) | Un metodo para producir una proteina de capside de papilomavirus | |
| RU2008102654A (ru) | Инактивированные химерные вакцины и связанные с ними способы применения | |
| DK0480949T3 (da) | Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse | |
| Le Grand et al. | AIDS vaccine developments | |
| DE3689622D1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| Lapham et al. | Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice | |
| WO2022039126A1 (ja) | ＳＡＲＳ－ＣｏＶ－２予防抗原ペプチドおよびその使用 | |
| Kensil et al. | Development of a genetically engineered vaccine against feline leukemia virus infection | |
| Zhaori et al. | Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines | |
| US4470967A (en) | Lectin-containing anti-viral vaccines for domestic animals and method of preparation | |
| Potter et al. | A new surface-antigen-adsorbed influenza virus vaccine II. Studies in a volunteer group | |
| EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
| Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice |